Volume 18, Number 12—December 2012
Research
Diagnostic Assays for Crimean-Congo Hemorrhagic Fever
Table 4
Parameter | IgM serology |
IgG serology |
Genome detection |
|||||
---|---|---|---|---|---|---|---|---|
ELISA | IFA | ELISA | IFA | qRT-PCR | LCD array | |||
No. samples tested | 138 | 90 | 137 | 92 | 71 | 70 | ||
No. true positive | 43 | 31 | 41 | 31 | 39 | 40 | ||
No. false negative | 6 | 2 | 10 | 5 | 10 | 8 | ||
No. true negative | 88 | 57 | 86 | 56 | 21 | 21 | ||
No. false positive | 1 | 0 | 0 | 0 | 1 | 1 | ||
Sensitivity, % (95% CI) | 87.8 (75.2–95.3) | 93.9 (79.8–99.3) | 80.4 (66.9–90.2) | 86.1 (70.5–95.3) | 79.6 (65.7–89.8) | 83.3 (69.8–92.5) | ||
Specificity, % (95% CI) | 98.9 (93.9–100.0) | 100.0 (93.7–100.0)† | 100.0 (95.8–100.0) | 100.0 (93.6–100.0) | 95.5 (77.2–99.9) | 95.5 (77.2–99.9) |
*CCHF, Crimean-Congo hemorrhagic fever; IFA, immunofluorescent assay; qRT-PCR, quantitative reverse transcription PCR; LCD, low-cost, low-density.
†One-sided 95% CI.
Page created: November 21, 2012
Page updated: November 21, 2012
Page reviewed: November 21, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.